Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 34

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Zhenoluten® Biologically active food supplement ZHENOLUTEN® contains a complex of low molecular weight peptides with a molecular weight of up to 5000 Da, isolated from the tissues of the triceps muscle of young animals - calves notolder than 12 months of age or pigs. ZHENOLUTEN® is available in capsules with an active substance content of 10 mg. ZHENOLUTEN® peptides regulate metabolic processes in ovarian cells, increase their reserve ca- pacity, have a beneficial effect on the body’s adaptation processes in extreme conditions, and have antioxidant properties, regulating the peroxidation processes in ovarian tissues. Experimental studies have shown that peptides have a tissue-specific effect on the cells of those tissues from which they are isolated. This allows us to assume the effectiveness of the use of ZHENOLUTEN® to restore the functions of the reproductive system in women with disorders of various origins. Age-related or pathological changes in ovarian function are characterized by the development of a complex symptom-complex with the manifestation of neuropsychic, vasomotor, and metabolic-endo- crine disorders, combined into the concept of «climacteric syndrome» (1, 4, 5). These disorders occur in women over the age of 45; they significantly reduce their quality of life. Currently, non-hormonal and hormonal medications are used to treat menopause and ovarian wasting syndrome, many of which have severe contraindications and side effects (2, 3): - Sympatholytics - reserpine, obsidan; - Anticholinergics - belladonna tincture; - Antihistamines - tavegil, suprastin; - Tranquilizers - tazepam; - Vitamins B1, B6, E; - Steroid estrogens - estradiol dipropionate, folliculin, ethinylestradiol, estriol; - Gestagens (progestins) - progesterone, turinal, norkolut, premalut-nor, pregnin; - Combined estrogen-gestagenic drugs - biseurin, non-ovlon; - etc. CLINICAL CHARACTERISTICS OF PATIENTS A clinical study of the efficacy of ZHENOLUTEN® was carried out at the Medical Center of the St. Petersburg Institute of Bioregulation and Gerontology from April to November 2011. The clinical study involved 39 women aged 45 to 53 years with a mild to moderate climacteric syn- drome diagnosis and 28 women aged 38 to 43 years diagnosed with the ovarian wasting syndrome (early climacteric syndrome). Patients complained of hot flashes to the head and upper body, accompanied by increased sweating, headache, and surges in blood pressure, pain in the heart, chills, tachycardia attacks at rest, a tendency to fainting, nausea, a feeling of «sinking» of the heart, dizziness, and weakness. Psychoemotional dis- orders were most often manifested by irritability, tearfulness, anxiety, sleep disturbances, decreased memory and attention, rapid fatigue, and decreased physical and mental performance. Patients noted an increase in the incidence of respiratory infectious diseases. During laboratory examination, the patients were found to have hormonal disorders characterized by increased levels of FSH and LH in the peripheral blood in patients with climacteric syndrome. More- over, in patients diagnosed with ovarian wasting syndrome, an increase in the level of FSH and LH was noted several times. It was accompanied by a significant decrease in estradiol content in the periph- eral blood. General clinical and biochemical parameters in the blood did not go beyond the age norm. All patients were divided into 4 groups: 2 control and 2 primary in accordance with the diagnoses. Pa- tients in both control groups received conventional therapy, which did not include hormonal drugs. In addition to conventional treatment, patients of both main groups received ZHENOLUTEN® 1 capsule 2 times a day with meals for 30 days. All patients were divided into 4 groups: 2 control and 2 primary following the diagnoses. Patients in both control groups received conventional therapy, which did not include hormonal drugs. In addi- tion to conventional treatment, patients of both primary groups received ZHENOLUTEN® 1 capsule 2 times a day with meals for 30 days.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.